Acute heart failure in the course of fulminant myocarditis requiring mechanical circulatory support in a healthy young patient after COVID-19

Marcinkiewicz, Kamil; Petryka-Mazurkiewicz, Joanna; Nowicki, Michał; Kuriata, Jarosław; Dzielińska, Zofia; Demkow, Marcin; Konopka, Anna

doi:10.33963/kp.15888

Cited by 9 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute myocarditis following vaccination is a rare but serious complication, which has until now been recognized as associated almost exclusively with smallpox and influenza immunization [2]. Myocarditis in the course of COVID-19 infection was previously described [3,4]; however, only recently have the first cases of acute myocarditis following administration of the mRNA-based anti-COVID-19 vaccines (Pfizer-BioNTech and Moderna) been reported [2,5]. This complication typically occurs in young adult males within 4 days after administration of the second dose of the COVID-19 vaccine [2,5].…”

mentioning

confidence: 99%

Every rose has its thorns — acute myocarditis following COVID-19 vaccination

2021

View full text Add to dashboard Cite

mentioning

confidence: 99%

Every rose has its thorns — acute myocarditis following COVID-19 vaccination

2021

View full text Add to dashboard Cite

“…However, clinical presentations of patients with COVID-19 myocarditis can vary from patient to patient. Some patients have relatively mild presentations such as cough, fever and dyspnea [ 9 , 10 , 22 , 66 , 67 ]. These symptoms may be due to COVID-19 itself and not the myocarditis.…”

Section: Presentation Of Covid-19 Myocarditismentioning

confidence: 99%

“…The disease course of COVID-19 myocarditis can range from mild to severe. If not treated, the myocarditis may progress to life-threatening heart failure and arrythmias; therefore, it is imperative for clinicians to recognize possible cases of COVID-19 myocarditis and treat them accordingly [ 9 – 11 ]. Moreover, it may lead to an increase in ward admissions in a time where hospitals can already be overwhelmed.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and myocarditis: a review of literature

et al. 2022

View full text Add to dashboard Cite

Myocarditis has been discovered to be a significant complication of coronavirus disease 2019 (COVID-19), a condition caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 myocarditis seems to have distinct inflammatory characteristics, which make it unique to other viral etiologies. The incidence of COVID-19 myocarditis is still not clear as a wide range of figures have been quoted in the literature; however, it seems that the risk of developing myocarditis increases with more severe infection. Furthermore, the administration of the mRNA COVID-19 vaccine has been associated with the development of myocarditis, particularly after the second dose. COVID-19 myocarditis has a wide variety of presentations, ranging from dyspnea and chest pain to acute heart failure and possibly death. It is important to catch any cases of myocarditis, particularly those presenting with fulminant myocarditis which can be characterized by signs of heart failure and arrythmias. Initial work up for suspected myocarditis should include serial troponins and electrocardiograms. If myocardial damage is detected in these tests, further screening should be carried out. Cardiac magnetic resonance imagining and endomyocardial biopsy are the most useful tests for myocarditis. Treatment for COVID-19 myocarditis is still controversial; however, the use of intravenous immunoglobulins and corticosteroids in combination may be effective, particularly in cases of fulminant myocarditis. Overall, the incidence of COVID-19 myocarditis requires further research, while the use of intravenous immunoglobulins and corticosteroids in conjunction requires large randomized controlled trials to determine their efficacy.

show abstract

“… 40 However, multiple case reports highlight the need for prompt identification, and management necessitates MCS with VA ECMO and biventricular Impella. 39 , 41 , 42 , 43 …”

Section: Special Considerationsmentioning

confidence: 99%

Acute Circulatory Collapse and Advanced Therapies in Patients with COVID-19 Infection

Thaker¹,

Shah²,

Kim³

et al. 2021

Methodist DeBakey Cardiovascular Journal

View full text Add to dashboard Cite

In the current era of the COVID-19 pandemic, intensive care patients with COVID-19 often develop respiratory failure and acute respiratory distress syndrome. While less frequent, acute circulatory collapse, with or without respiratory failure, has its own management challenges and nuances. Early identification of acute circulatory collapse requires appropriate imaging, particularly echocardiography, and precise diagnosis of cardiogenic shock using a Swan-Ganz catheter. Escalation to mechanical circulatory support (MCS), such as an intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation, has been useful in patients with acute circulatory collapse from COVID-19. This condition is associated with high morbidity and mortality, but early recognition of appropriate candidates for specific treatment strategies and escalation to MCS might improve outcomes.

show abstract

Acute heart failure in the course of fulminant myocarditis requiring mechanical circulatory support in a healthy young patient after COVID-19

Cited by 9 publications

References 4 publications

Every rose has its thorns — acute myocarditis following COVID-19 vaccination

Every rose has its thorns — acute myocarditis following COVID-19 vaccination

COVID-19 and myocarditis: a review of literature

Acute Circulatory Collapse and Advanced Therapies in Patients with COVID-19 Infection

Contact Info

Product

Resources

About